{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:28:37Z","timestamp":1792718917152,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["207472\/Z\/17\/Z"],"award-info":[{"award-number":["207472\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report the identification and results of susceptibility testing for fungal isolates from the cornea or contact lens care systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this retrospective epidemiological study, we searched the results of fungal cultures from cornea or contact lens systems referred for identification and susceptibility testing to the United Kingdom National Mycology Reference Laboratory between October 2016 and March 2022. For each fungal isolate, we recorded the genus and species of the fungus and the minimum inhibitory concentration (MIC) to six antifungal agents available to treat corneal infection (amphotericin, econazole, itraconazole, natamycin, posaconazole, and voriconazole).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 600 isolates from 585 patients, comprising 374 (62%) from corneal samples and 226 from contact lenses and care systems, of which 414 (69%) isolates were moulds (filamentous fungi) and 186 (31%) were yeasts. The most frequent moulds isolated were\n                      <jats:italic>Fusarium spp<\/jats:italic>\n                      (234 isolates, 39%) and\n                      <jats:italic>Aspergillus spp<\/jats:italic>\n                      (62, 10%). The most frequent yeasts isolated were\n                      <jats:italic>Candida spp<\/jats:italic>\n                      (112, 19%), predominantly\n                      <jats:italic>Candida parapsilosis<\/jats:italic>\n                      (65, 11%) and\n                      <jats:italic>Candida albicans<\/jats:italic>\n                      (33, 6%), with 35 isolates (6%) of\n                      <jats:italic>Meyerozyma guilliermondii<\/jats:italic>\n                      . In vitro susceptibility was greatest for natamycin (347 moulds tested, mode 4\u2009mg\/L, range 0.25\u201364\u2009mg\/L; 98 yeasts tested, mode 4\u2009mg\/L, range 0.5\u201332\u2009mg\/L), with susceptibility for 94% for moulds and 99% yeasts. Of the 16 isolates interpreted as highly resistant to natamycin (MIC\u2009\u226516\u2009mg\/L), 13 were\n                      <jats:italic>Aspergillus flavus<\/jats:italic>\n                      complex.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In vitro susceptibility supports the use of natamycin for the empiric treatment of fungal keratitis in the UK.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-023-02719-1","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:02:37Z","timestamp":1694149357000},"page":"529-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-5192","authenticated-orcid":false,"given":"Stephen","family":"Tuft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil R. H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1872-9169","authenticated-orcid":false,"given":"Matthew J.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Borman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"2719_CR1","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S1473-3099(20)30448-5","volume":"21","author":"L Brown","year":"2021","unstructured":"Brown L, Leck AK, Gichangi M, Burton MJ, Denning DW. The global incidence and diagnosis of fungal keratitis. Lancet Infect Dis. 2021;21:e49\u201357.","journal-title":"Lancet Infect Dis"},{"key":"2719_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/jof7040273","volume":"7","author":"JJ Hoffman","year":"2021","unstructured":"Hoffman JJ, Burton MJ, Leck A. Mycotic Keratitis\u2014A Global Threat from the Filamentous Fungi. J Fungi (Basel). 2021;7:273.","journal-title":"J Fungi (Basel)"},{"key":"2719_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ajo.2008.04.019","volume":"146","author":"L Xie","year":"2008","unstructured":"Xie L, Zhai H, Zhao J, Sun S, Shi W, Dong X. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China. Am J Ophthalmol. 2008;146:260\u20135.","journal-title":"Am J Ophthalmol"},{"key":"2719_CR4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/eye.2017.82","volume":"31","author":"S Farrell","year":"2017","unstructured":"Farrell S, McElnea E, Moran S, Knowles S, Murphy CC. Fungal keratitis in the Republic of Ireland. Eye. 2017;31:427\u20131434.","journal-title":"Eye"},{"key":"2719_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/aos.12440","volume":"93","author":"SE Nielsen","year":"2015","unstructured":"Nielsen SE, Nielsen E, Julian HO, Lindegaard J, H\u00f8jgaard K, Ivarsen A, et al. Incidence and clinical characteristics of fungal keratitis in a Danish population from 2000 to 2013. Acta Ophthalmol. 2015;93:54\u201358.","journal-title":"Acta Ophthalmol"},{"key":"2719_CR6","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/eye.2008.298","volume":"23","author":"SJ Tuft","year":"2009","unstructured":"Tuft SJ, Tullo AB. Fungal keratitis in the United Kingdom 2003-2005. Eye. 2009;23:1308\u201313.","journal-title":"Eye"},{"key":"2719_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/aos.14910","volume":"100","author":"R Olivier","year":"2022","unstructured":"Olivier R, Knoeri J, Leveziel L, Negrier P, Georgeon C, Kobal A, et al. Update on fungal keratitis in France: a case-control study. Acta Ophthalmol. 2022;100:159\u201363.","journal-title":"Acta Ophthalmol"},{"key":"2719_CR8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00347-019-0871-9","volume":"116","author":"M Roth","year":"2019","unstructured":"Roth M, Daas L, Renner-Wilde A, Cvetkova-Fischer N, Saeger M, Herwig-Carl M, et al. The German keratomycosis registry: Initial results of a multicenter survey. Ophthalmology. 2019;116:957\u201366.","journal-title":"Ophthalmology"},{"key":"2719_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ajo.2016.05.021","volume":"168","author":"HS Ong","year":"2016","unstructured":"Ong HS, Fung SSM, Macleod D, Dart JKG, Tuft SJ, Burton MJ. Altered patterns of fungal keratitis at a london ophthalmic referral hospital: an eight-year retrospective observational study. Am J Ophthalmol. 2016;168:227\u201336.","journal-title":"Am J Ophthalmol"},{"key":"2719_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fcimb.2020.00133","volume":"10","author":"C Oliveira dos Santos","year":"2020","unstructured":"Oliveira dos Santos C, Kolwijck E, van Rooij J, Stoutenbeek R, Visser N, Cheng YY, et al. Epidemiology and clinical management of Fusarium keratitis in the Netherlands, 2005\u20132016. Front Cell Infect Microbiol. 2020;10:133.","journal-title":"Front Cell Infect Microbiol"},{"key":"2719_CR11","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/bjo.2005.076315","volume":"89","author":"PA Thomas","year":"2005","unstructured":"Thomas PA, Leck AK, Myatt M. Characteristic clinical features as an aid to the diagnosis of suppurative keratitis caused by filamentous fungi. Br J Ophthalmol. 2005;89:1554\u20138.","journal-title":"Br J Ophthalmol"},{"key":"2719_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajo.2007.02.030","volume":"143","author":"MA Dahlgren","year":"2007","unstructured":"Dahlgren MA, Lingappan A, Wilhelmus KR. The clinical diagnosis of microbial keratitis. Am J Ophthalmol. 2007;143:940\u20134.","journal-title":"Am J Ophthalmol"},{"key":"2719_CR13","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/jof8090955","volume":"8","author":"JJ Hoffman","year":"2022","unstructured":"Hoffman JJ, Yadav R, Sanyam SD, Chaudhary P, Roshan A, Singh SK, et al. Diagnosis of Fungal keratitis in low-income countries: evaluation of smear microscopy, culture, and in vivo confocal microscopy in Nepal. J Fungi (Basel). 2022;8:955.","journal-title":"J Fungi (Basel)"},{"key":"2719_CR14","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1128\/JCM.00477-16","volume":"54","author":"AM Borman","year":"2016","unstructured":"Borman AM, Desnos-Ollivier M, Campbell CK, Bridge PD, Dannaoui E, Johnson EM. Novel Taxa associated with human fungal black-grain mycetomas: emarellia grisea gen. nov., sp. nov., and Emarellia paragrisea sp. nov. J Clin Microbiol. 2016;54:1738\u201345.","journal-title":"J Clin Microbiol"},{"key":"2719_CR15","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1128\/JCM.02459-16","volume":"55","author":"AM Borman","year":"2017","unstructured":"Borman AM, Fraser M, Szekely A, Larcombe DE, Johnson EM. Rapid Identification of Clinically Relevant Members of the Genus Exophiala by Matrix-Assisted Laser Desorption Ionization\u2013Time of Flight Mass Spectrometry and Description of Two Novel Species, Exophiala campbellii and Exophiala lavatrina. J Clin Microbiol. 2017;55:1162\u201376.","journal-title":"J Clin Microbiol"},{"key":"2719_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/vr.164.11.342","volume":"164","author":"VR Simpson","year":"2009","unstructured":"Simpson VR, Davison NJ, Borman AM, Linton CJ, Everest D. Fatal candidiasis in a wild red squirrel (Sciurus vulgaris). Vet Rec. 2009;164:342\u20134.","journal-title":"Vet Rec"},{"key":"2719_CR17","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. Document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA. 2012."},{"key":"2719_CR18","unstructured":"Clinical and laboratory standards institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard, M38-A2. Vilanova: Clinical and Laboratory Standards Institute 2008."},{"key":"2719_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/jof7040271","volume":"7","author":"AM Borman","year":"2021","unstructured":"Borman AM, Fraser M, Patterson Z, Palmer MD, Johnson EM. In vitro antifungal drug resistance profiles of clinically relevant members of the mucorales (Mucoromycota) especially with the newer triazoles. J Fungi (Basel). 2021;7:271.","journal-title":"J Fungi (Basel)"},{"key":"2719_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1128\/jcm.24.1.21-25.1986","volume":"24","author":"RB Simmons","year":"1986","unstructured":"Simmons RB, Buffington JR, Ward M, Wilson LA, Ahearn DG. Morphology and ultrastructure of fungi in extended-wear soft contact lenses. J Clin Microbiol. 1986;24:21\u201325.","journal-title":"J Clin Microbiol"},{"key":"2719_CR21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jama.296.8.953","volume":"296","author":"DC Chang","year":"2006","unstructured":"Chang DC, Grant GB, O\u2019Donnell K, Wannemuehler KA, Noble-Wang J, Rao CY, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA. 2006;296:953\u201363.","journal-title":"JAMA"},{"key":"2719_CR22","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1001\/jama.295.24.2867","volume":"295","author":"W-B Khor","year":"2006","unstructured":"Khor W-B, Aung T, Saw S-M, Wong T-Y, Tambyah PA, Tan A-L, et al. An outbreak of Fusarium Keratitis associated with contact lens wear in Singapore. JAMA. 2006;295:2867\u201373.","journal-title":"JAMA"},{"key":"2719_CR23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ophtha.2021.12.004","volume":"129","author":"JJ Hoffman","year":"2022","unstructured":"Hoffman JJ, Yadav R, Sanyam SD, Chaudhary P, Roshan A, Singh SK, et al. Topical Chlorhexidine 0.2% versus Topical Natamycin 5% for the Treatment of Fungal Keratitis in Nepal: A Randomized Controlled Noninferiority Trial. Ophthalmology. 2022;129:530\u201341.","journal-title":"Ophthalmology"},{"key":"2719_CR24","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/bjophthalmol-2014-306485","volume":"99","author":"S Sharma","year":"2015","unstructured":"Sharma S, Das S, Virdi A, Fernandes M, Sahu SK, Kumar Koday N, et al. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. Br J Ophthalmol. 2015;99:1190\u20135.","journal-title":"Br J Ophthalmol"},{"key":"2719_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1001\/jamaophthalmol.2013.1497","volume":"131","author":"NV Prajna","year":"2013","unstructured":"Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol. 2013;131:422\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"2719_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ophtha.2005.10.063","volume":"113","author":"P Lalitha","year":"2006","unstructured":"Lalitha P, Prajna NV, Kabra A, Mahadevan K, Srinivasan M. Risk factors for treatment outcome in fungal keratitis. Ophthalmology. 2006;113:526\u201330.","journal-title":"Ophthalmology"},{"key":"2719_CR27","first-page":"CD004241","volume":"4","author":"NV FlorCruz","year":"2015","unstructured":"FlorCruz NV, Evans JR. Medical interventions for fungal keratitis. Cochrane Database Syst Rev. 2015;4:CD004241.","journal-title":"Cochrane Database Syst Rev"},{"key":"2719_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/01.ico.0000151539.92865.3e","volume":"24","author":"CM Kalavathy","year":"2005","unstructured":"Kalavathy CM, Parmar P, Kaliamurthy J, Philip VR, Ramalingam MDK, Jesudasan CAN, et al. Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis. Cornea. 2005;24:449\u201352.","journal-title":"Cornea"},{"key":"2719_CR29","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/bjo.87.10.1235","volume":"87","author":"NV Prajna","year":"2003","unstructured":"Prajna NV, John RK, Nirmalan PK, Lalitha P, Srinivasan M. A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. Br J Ophthalmol. 2003;87:1235\u20137.","journal-title":"Br J Ophthalmol"},{"key":"2719_CR30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/bjo.2009.158675","volume":"94","author":"BL Shapiro","year":"2010","unstructured":"Shapiro BL, Lalitha P, Loh AR, Fothergill AW, Prajna NV, Srinivasan M, et al. Susceptibility testing and clinical outcome in fungal keratitis. Br J Ophthalmol. 2010;94:384\u20135.","journal-title":"Br J Ophthalmol"},{"key":"2719_CR31","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ophtha.2014.03.004","volume":"121","author":"CQ Sun","year":"2014","unstructured":"Sun CQ, Lalitha P, Prajna NV, Karpagam R, Geetha M, O\u2019Brien KS, et al. Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis. Ophthalmology. 2014;121:1495\u2013500.","journal-title":"Ophthalmology"},{"key":"2719_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ajo.2013.10.004","volume":"157","author":"P Lalitha","year":"2014","unstructured":"Lalitha P, Sun CQ, Prajna NV, Karpagam R, Geetha M, O\u2019Brien KS, et al. In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial. Am J Ophthalmol. 2014;157:318\u201326.","journal-title":"Am J Ophthalmol"},{"key":"2719_CR33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archopht.125.6.789","volume":"125","author":"P Lalitha","year":"2007","unstructured":"Lalitha P, Shapiro BL, Srinivasan M, Prajna NV, Acharya NR, Fothergill AW, et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol. 2007;125:789\u201393.","journal-title":"Arch Ophthalmol"},{"key":"2719_CR34","doi-asserted-by":"publisher","first-page":"6395840","DOI":"10.1155\/2019\/6395840","volume":"2019","author":"P Manikandan","year":"2019","unstructured":"Manikandan P, Abdel-Hadi A, Randhir Babu Singh Y, Revathi R, Anita R, Banawas S, et al. Fungal Keratitis: Epidemiology, Rapid Detection, and Antifungal Susceptibilities of Fusarium and Aspergillus Isolates from Corneal Scrapings. Biomed Res Int. 2019;2019:6395840.","journal-title":"Biomed Res Int"},{"key":"2719_CR35","first-page":"227","volume":"106","author":"EC Alfonso","year":"2008","unstructured":"Alfonso EC. Genotypic identification of Fusarium species from ocular sources: comparison to morphologic classification and antifungal sensitivity testing (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:227\u201339.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2719_CR36","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1128\/JCM.00649-17","volume":"55","author":"G Walther","year":"2017","unstructured":"Walther G, Stasch S, Kaerger K, Hamprecht A, Roth M, Cornely OA, et al. Fusarium Keratitis in Germany. J Clin Microbiol. 2017;55:2983\u201395.","journal-title":"J Clin Microbiol"},{"key":"2719_CR37","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/jof8050476","volume":"8","author":"T-E Huang","year":"2022","unstructured":"Huang T-E, Ou J-H, Hung N, Yeh L-K, Ma DH-K, Tan H-Y, et al. Fusarium Keratitis in Taiwan: Molecular Identification, Antifungal Susceptibilities, and Clinical Features. J Fungi (Basel). 2022;8:476.","journal-title":"J Fungi (Basel)"},{"key":"2719_CR38","doi-asserted-by":"publisher","first-page":"e02669","DOI":"10.1128\/AAC.02669-18","volume":"63","author":"C Oliveira Dos Santos","year":"2019","unstructured":"Oliveira Dos Santos C, Kolwijck E, van der Lee HA, Tehupeiory-Kooreman MC, Al-Hatmi AMS, Matayan E, et al. In Vitro Activity of Chlorhexidine Compared with Seven Antifungal Agents against 98 Fusarium Isolates Recovered from Fungal Keratitis Patients. Antimicrob Agents Chemother. 2019;63:e02669\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"2719_CR39","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/ICO.0b013e318277ac74","volume":"32","author":"RA Oechsler","year":"2013","unstructured":"Oechsler RA, Feilmeier MR, Miller D, Shi W, Hofling-Lima AL, Alfonso EC. Fusarium keratitis: genotyping, in vitro susceptibility and clinical outcomes. Cornea. 2013;32:667\u201373.","journal-title":"Cornea"},{"key":"2719_CR40","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3109\/02713688609029240","volume":"5","author":"DM O\u2019Day","year":"1986","unstructured":"O\u2019Day DM, Head WS, Robinson RD, Clanton JA. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res. 1986;5:877\u201382.","journal-title":"Curr Eye Res"},{"key":"2719_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archophthalmol.2007.71","volume":"126","author":"D Lau","year":"2008","unstructured":"Lau D, Fedinands M, Leung L, Fullinfaw R, Kong D, Davies G, et al. Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective open-label study. Arch Ophthalmol. 2008;126:343\u20136.","journal-title":"Arch Ophthalmol"},{"key":"2719_CR42","doi-asserted-by":"publisher","first-page":"6896","DOI":"10.1128\/AAC.00683-16","volume":"60","author":"CF Neoh","year":"2016","unstructured":"Neoh CF, Leung L, Chan E, Al-Badriyeh D, Fullinfaw RO, Jhanji V, et al. Open-label study of absorption and clearance of 1% voriconazole eye drops. Antimicrob Agents Chemother. 2016;60:6896\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2719_CR43","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3109\/02713683.2010.506968","volume":"35","author":"S Senthilkumari","year":"2010","unstructured":"Senthilkumari S, Lalitha P, Prajna NV, Haripriya A, Nirmal J, Gupta P, et al. Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans. Curr Eye Res. 2010;35:953\u201360.","journal-title":"Curr Eye Res"},{"key":"2719_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/archophthalmol.2007.8","volume":"126","author":"GA Vemulakonda","year":"2008","unstructured":"Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, Van. Gelder RN. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol. 2008;126:18\u201322.","journal-title":"Arch Ophthalmol"},{"key":"2719_CR45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1128\/AAC.00762-06","volume":"51","author":"MA Thiel","year":"2007","unstructured":"Thiel MA, Zinkernagel AS, Burhenne J, Kaufmann C, Haefeli WE. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother. 2007;51:239\u201344.","journal-title":"Antimicrob Agents Chemother"},{"key":"2719_CR46","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/jop.2017.0139","volume":"34","author":"X Zhao","year":"2018","unstructured":"Zhao X, Tong Y, Wang X, Zhang X, Chen S, Lu H. Comparison of the ocular penetration and pharmacokinetics between natamycin and voriconazole after topical instillation in rabbits. J Ocul Pharm Ther. 2018;34:460\u20137.","journal-title":"J Ocul Pharm Ther"},{"key":"2719_CR47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/myc.12469","volume":"59","author":"SS Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves SS, Souza ACR, Chowdhary A, Meis JF, Colombo AL. Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus. Mycoses. 2016;59:198\u2013219.","journal-title":"Mycoses"},{"key":"2719_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/mmy\/myx144","volume":"56","author":"A Resendiz Sharpe","year":"2018","unstructured":"Resendiz Sharpe A, Lagrou K, Meis JF, Chowdhary A, Lockhart SR, Verweij PE, et al. Triazole resistance surveillance in Aspergillus fumigatus. Med Mycol. 2018;56:83\u201392.","journal-title":"Med Mycol"},{"key":"2719_CR49","doi-asserted-by":"publisher","first-page":"e1003633","DOI":"10.1371\/journal.ppat.1003633","volume":"9","author":"A Chowdhary","year":"2013","unstructured":"Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of Azole-Resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 2013;9:e1003633.","journal-title":"PLoS Pathog"},{"key":"2719_CR50","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1167\/iovs.12-9848","volume":"53","author":"PK Mukherjee","year":"2012","unstructured":"Mukherjee PK, Chandra J, Yu C, Sun Y, Pearlman E, Ghannoum MA. Characterization of fusarium keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis. Invest Ophthalmol Vis Sci. 2012;53:4450\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2719_CR51","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10384-022-00907-2","volume":"66","author":"K Kimura","year":"2022","unstructured":"Kimura K, Inoue Y, Asari S, Sunada A, Ohashi Y, Shimomura Y, et al. Multicenter prospective observational study of fungal keratitis in Japan: analyses of in vitro susceptibility tests for combinations of drugs. Jpn J Ophthalmol. 2022;66:240\u201353.","journal-title":"Jpn J Ophthalmol"},{"key":"2719_CR52","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamaophthalmol.2021.5765","volume":"140","author":"NV Prajna","year":"2022","unstructured":"Prajna NV, Lalitha P, Krishnan T, Rajaraman R, Radnakrishnan N, Srinivasan M, et al. Patterns of antifungal resistance in adult patients with fungal keratitis in South India: a post hoc analysis of 3 randomized clinical trials. JAMA Ophthalmol. 2022;140:179\u201384.","journal-title":"JAMA Ophthalmol"},{"key":"2719_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-022-02616-8","author":"N Tang","year":"2023","unstructured":"Tang N, Huang G, Lei D, Jiang L, Chen Q, He W, et al. An artificial intelligence approach to classify pathogenic fungal genera of fungal keratitis using corneal confocal microscopy images. Int Ophthalmol. 2023. https:\/\/doi.org\/10.1007\/s10792-022-02616-8","journal-title":"Int Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02719-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02719-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02719-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T08:03:44Z","timestamp":1707465824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02719-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2719"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02719-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2811881\/v1","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"13 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}